Vaxin’s Pandemic Vaccine Spotlighted

Aug. 13, 2008 - PRLog -- Contact:
Bill Enright
President & CEO
Phone: 205-909-3751
Email: enright@vaxin.com

FOR IMMEDIATE RELEASE

VAXIN’S PANDEMIC VACCINE SPOTLIGHTED

Promising data presented at Immunotherapeutics & Vaccine Summit

Birmingham, Alabama --August 13, 2008—Vaxin’s lead vaccine candidate, targeting avian influenza, is being featured today at the Immunotherapeutics & Vaccine Summit in Boston.  Kent Van Kampen, Vaxin’s Chief Operating Officer and a highly respected authority on vaccine development, will be presenting the company’s recent findings.  

Responding to the ongoing international concern that a particularly virulent form of avian influenza may become highly infectious in humans, Vaxin has developed a vaccine which can be rapidly produced and mass administered.  “Our vaccine uses a neutered cold virus to carry a tiny snippet of influenza DNA, rather than the entire influenza virus,” said Dr. Van Kampen.  “When the immune system responds, it actually learns how to be immune to the target disease – avian influenza in this case,” he said.

This vaccine has already been shown to provide excellent protection when administered to poultry before hatching, a technique called in-ovo vaccination which is well suited for automation.  Vaxin has utilized these advances to develop a version of the vaccine that will soon be tested in humans.  Dr. Van Kampen said, “We have data from a previous human trial which demonstrated a promising immune response against a seasonal flu strain  and we have high expectations for our upcoming pandemic flu vaccine trial.”

Billed as the "Leading International Vaccine Event", Cambridge Healthtech Institute’s Third Annual Immunotherapeutics & Vaccine Summit brings together vaccine professionals from companies, government agencies, academics, and nonprofit institutes, to discuss issues surrounding the development of today’s vaccines around the world.  “We are pleased to be able to share our progress with such a distinguished group of colleagues,” said Dr. Van Kampen.  

By protecting two routes of potential spread, humans and poultry, Vaxin’s pandemic avian influenza vaccines could provide an excellent defense against a worldwide pandemic.  The poultry vaccine would also protect a vital food industry in the process.



Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected.  These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

#   #   #

# # #

About Vaxin:

Vaxin Inc. is an emerging vaccine company with a lead in the development of needle-free, single dose highly effective vaccines. These vaccines are safely administered into the nose or onto the skin, taking the battle against diseases to the immune system’s front lines where diseases attack, rather than injecting the vaccine inside the body where the body’s immune response is actually weaker. This also allows Vaxin’s vaccines to be mass administered by personnel without sophisticated medical training.

The company’s technology platform also provides a critical tool for the rapid production of vaccines against influenza, avian influenza, anthrax, and Alzheimer’s disease utilizing molecular techniques and state of the art cell culture based manufacturing. Vaxin’s vaccines are not dependent on chicken eggs and can therefore be more reliably produced even in the event of avian epidemics. Vaxin’s technology also has applications for animal health uses.